Clinical trial
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid…
NCT00359294 · PharmaMar, Industry · Terminated
Key facts
| NCT number | NCT00359294 |
|---|---|
| Title | A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma |
| Official title | A Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Study of PM00104 Administered Intravenously Over 1 Hour Daily for 5 Days, Every 3 Weeks, to Subjects With Advanced Malignant Solid Tumors or Lymphoma. |
| Lead sponsor | PharmaMar, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors, Lymphoma |
| Intervention type | Drug |
| Interventions | PM00104 |
| Enrollment | 12 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 2, 2006 |
| Last update posted | Jul 28, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: